Zenith Capital (Zenith Capital) Cash-to-Debt : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zenith Capital's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zenith Capital couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for Zenith Capital's Cash-to-Debt or its related term are showing as below:

ZHCLF's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.315
* Ranked among companies with meaningful Cash-to-Debt only.

Zenith Capital Cash-to-Debt Historical Data

The historical data trend for Zenith Capital's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zenith Capital Cash-to-Debt Chart

Zenith Capital Annual Data

Trend

Cash-to-Debt

Zenith Capital Quarterly Data

Cash-to-Debt

Competitive Comparison of Zenith Capital's Cash-to-Debt

For the Biotechnology subindustry, Zenith Capital's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Cash-to-Debt falls into.

Zenith Capital Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zenith Capital's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Zenith Capital's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Zenith Capital (OTCPK:ZHCLF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zenith Capital Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines